AuricX Pharmaceuticals

Auricx Pharmaceuticals, Inc. focuses on providing new treatments for methicillin-resistant Staphylococcus aureus (MRSA). It offers BPH-652, an anti-cholesterol compound in clinical trials, designed to make Staphylococcus aureus more susceptible to the immune system and antibiotics. The company is also developing an orally bioavailable formulation of the antibiotic vancomycin.